Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

F. Palandri, G.A. Palumbo, E. Abruzzese, A. Iurlo, N. Polverelli, E. Elli, M. Bonifacio, M. Bergamaschi, B. Martino, M. Tiribelli, G. Benevolo, A. Tieghi, N. Sgherza, A. Isidori, G. Binotto, M. Crugnola, F. Heidel, F. Cavazzini, C. Bosi, G. AuteriD. Cattaneo, R. Foà, R.M. Lemoli, A. Cuneo, M. Krampera, D. Bartoletti, M. Cavo, N. Vianelli, M. Breccia, R. Latagliata

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib'. Together they form a unique fingerprint.

Medicine & Life Sciences